The identification of a minimal, high-potency glucagon antagonist capable of sustained in vivo action represents a significant advancement in the development of therapeutics for acute hyperglycemic emergencies. This study focuses on [Pla6, Asp28]glucagon(6-29) amide (26), a truncated peptide derived from systematic structure-function analysis of the glucagon sequence, designed to achieve full antagonism with optimized pharmacological properties.
Initial investigations revealed that deletion of His1 and substitution of Glu9 with aspartic acid transform glucagon into a functional antagonist. Further N-terminal truncation identified [Glu9]glucagon(6-29) amide (11) as the shortest fragment retaining full antagonistic activity, with an IC50 of 36 nM in competitive binding assays. However, its potency was limited by suboptimal receptor affinity and short half-life. To address this, Phe6 was replaced with L-3-phenyllactic acid (Pla), a non-natural phenylalanine surrogate that preserves key hydrophobic interactions while enhancing binding affinity.Nkx2.2 Antibody Autophagy The resulting analogue, [Pla6, Glu9]glucagon(6-29) amide (21), demonstrated a threefold improvement in potency (IC50 = 12 nM). Subsequent substitution of Glu9 with Asp28 yielded compound 26, which exhibited further enhancement in inhibitory potency (IC50 = 9 nM) and significantly improved aqueous solubility—critical for intravenous formulation.
Functional characterization confirmed that 26 acts as a full antagonist with no residual agonist activity in cAMP accumulation assays across human and mouse glucagon receptors. Selectivity profiling showed negligible activity at GLP-1R and GIPR, confirming target specificity. The incorporation of a palmitoyl group at Lys10 via a glutamate-glutamate linker produced the fatty-acylated analogue 31, which displayed markedly prolonged circulation time due to increased plasma protein binding and reduced renal clearance.
Pharmacokinetic evaluation in lean C57BL/6 mice following subcutaneous administration revealed that peptide 26 achieved a peak plasma concentration (Cmax) of 261 nM within 45 minutes, with a half-life of 30.7 minutes. In contrast, peptide 31 reached a Cmax of 3,310 nM after 4 hours and exhibited a half-life of 6.73 hours, demonstrating a more than 13-fold extension in duration. Total exposure (AUC) for 31 was 37,400 h·nM compared to 209 h·nM for 26, underscoring the impact of lipid conjugation.RHOA Antibody supplier
In vivo glucagon challenge tests validated the functional efficacy of both compounds.PMID:35041020 Peptide 26 fully suppressed glucose elevation when administered 15 minutes prior to glucagon injection. Remarkably, the palmitoylated form 31 maintained complete inhibition even when dosed 24 hours earlier, indicating robust long-term activity. This sustained effect is particularly valuable in clinical scenarios where delayed intervention may be necessary or where continuous suppression is required.
Chemical stability assessments confirmed that both peptides remained intact after incubation in PBS at physiological temperatures, with no detectable degradation or aggregation. Formulation studies using propylene glycol prevented physical precipitation, supporting feasibility for subcutaneous delivery.
These findings establish [Pla6, Asp28]glucagon(6-29) amide (26) and its palmitoylated derivative 31 as highly promising candidates for managing acute hyperglycemia. Their combination of minimal sequence length, high potency, full antagonism, selectivity, and tunable pharmacokinetics offers a unique therapeutic profile suited for emergency settings. Future work will focus on advancing these agents into preclinical safety and efficacy models of diabetic ketoacidosis and hyperosmolar hyperglycemic state, paving the way for potential clinical translation as rapid-onset, long-duration glucagon antagonists.MedChemExpress (MCE) offers a wide range of high-quality research chemicals and biochemicals (novel life-science reagents, reference compounds and natural compounds) for scientific use. We have professionally experienced and friendly staff to meet your needs. We are a competent and trustworthy partner for your research and scientific projects.Related websites: https://www.medchemexpress.com